Patents by Inventor Jole FIORITO
Jole FIORITO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11851427Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.Type: GrantFiled: December 30, 2020Date of Patent: December 26, 2023Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Donald W. Landry, Shixian Deng, Ottavio Arancio, Jole Fiorito, Andrew Wasmuth
-
Publication number: 20230165813Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.Type: ApplicationFiled: August 4, 2022Publication date: June 1, 2023Inventors: Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL, Donald W. LANDRY, Ottavio ARANCIO, Luigi SCOTTO, Shixian DENG, Rosa PURGATORIO, Jole FIORITO
-
Publication number: 20220125748Abstract: The invention provides for compounds that are HAT activators or inhibitors. The invention further provides a method for treating neurodegenerative diseases, cancer and other malignant conditions, or to increase memory in a subject not suffering from a neurodegenerative disease by administering HAT activators or inhibitors to a subject in need thereof. The method further comprises co-administration of HD AC inhibitors with HAT activators or HD AC activators with HAT inhibitors.Type: ApplicationFiled: February 7, 2020Publication date: April 28, 2022Inventors: Ottavio ARANCIO, Donald W. LANDRY, Shixian DENG, Jennifer Effie AMENGUAL, Elisa ZUCCARELLO, Jole FIORITO, Yuxuan LIU, Elisa CALCAGNO, Luuk Elard DE VRIES
-
Publication number: 20220127232Abstract: Compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.Type: ApplicationFiled: February 7, 2020Publication date: April 28, 2022Inventors: Ottavio ARANCIO, Elisa ZUCCARELLO, Elisa CALCAGNO, Donald W. LANDRY, Shixian DENG, Jole FIORITO, Luuk Elard DE VRIES, Christopher John YARNOLD, Richard Scott JONES, Julian Hugh ROWLEY
-
Patent number: 11191768Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.Type: GrantFiled: December 2, 2019Date of Patent: December 7, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Ottavio Arancio, Shixian Deng, Donald W. Landry, Jole Fiorito, Rosa Purgatorio, Owen Anthony O'Connor, Jennifer Effie Amengual
-
Publication number: 20210130349Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.Type: ApplicationFiled: December 30, 2020Publication date: May 6, 2021Inventors: Donald W. LANDRY, Shixian DENG, Ottavio ARANCIO, Jole FIORITO, Andrew WASMUTH
-
Patent number: 10899756Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.Type: GrantFiled: July 17, 2014Date of Patent: January 26, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Donald W. Landry, Shixian Deng, Ottavio Arancio, Jole Fiorito, Andrew Wasmuth
-
Publication number: 20200330410Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.Type: ApplicationFiled: May 8, 2020Publication date: October 22, 2020Inventors: Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL, Donald W. LANDRY, Ottavio ARANCIO, Luigi SCOTTO, Shixian DENG, Rosa PURGATORIO, Jole FIORITO
-
Patent number: 10653648Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.Type: GrantFiled: July 20, 2017Date of Patent: May 19, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Owen Anthony O'Connor, Jennifer Effie Amengual, Donald W. Landry, Ottavio Arancio, Luigi Scotto, Shixian Deng, Rosa Purgatorio, Jole Fiorito
-
Patent number: 10626113Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.Type: GrantFiled: July 17, 2014Date of Patent: April 21, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Donald W. Landry, Shixian Deng, Ottavio Arancio, Jole Fiorito, Andrew Wasmuth
-
Publication number: 20200101078Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tan protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.Type: ApplicationFiled: December 2, 2019Publication date: April 2, 2020Inventors: Ottavio ARANCIO, Shixian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL
-
Publication number: 20180360842Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.Type: ApplicationFiled: January 11, 2018Publication date: December 20, 2018Inventors: Ottavio ARANCIO, Shi Xian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL
-
Publication number: 20180244603Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels and/or accumulations of alpha-synuclein as well as cancer by administering a compound hat modulates HAT to a subject.Type: ApplicationFiled: May 1, 2018Publication date: August 30, 2018Inventors: Yitshak FRANCIS, Mauro FA, Ottavio ARANCIO, Jole FIORITO, Shixian DENG, Donald W. LANDRY, Michal LUZAC, Yan FENG
-
Patent number: 9969677Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.Type: GrantFiled: December 22, 2011Date of Patent: May 15, 2018Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Yitshak Francis, Mauro Fa, Ottavio Arancio, Jole Fiorito, Shixian Deng, Donald W. Landry, Michal Luzac, Yan Feng
-
Publication number: 20180021273Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.Type: ApplicationFiled: July 20, 2017Publication date: January 25, 2018Inventors: Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL, Donald W. LANDRY, Ottavio ARANCIO, Luigi SCOTTO, Shi Xian DENG, Rosa PURGATORIO, Jole FIORITO
-
Publication number: 20170182054Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.Type: ApplicationFiled: March 30, 2015Publication date: June 29, 2017Inventors: Ottavio ARANCIO, Shixian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL
-
Publication number: 20170121276Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.Type: ApplicationFiled: December 22, 2011Publication date: May 4, 2017Applicant: The Trustees of Columbia University in the City of New YorkInventors: Yitshak FRANCIS, Mauro FA, Ottavio ARANCIO, Jole FIORITO, Shixian DENG, Donald W. LANDRY, Michal LUZAC, Yan FENG
-
Publication number: 20140329804Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Donald W. LANDRY, Shixian DENG, Ottavio ARANCIO, Jole FIORITO, Andrew WASMUTH